Stallergenes Greer Plc announced that Health Canada accepted for review the company’s New Drug Submission (NDS) for STG320, an investigational sublingual immunotherapy tablet for the treatment of house dust mite (HDM) induced allergic rhinitis. Once a New Drug Submission is accepted for review it takes usually between nine to twelve months for Health Canada to issue the results of the evaluation. The company’s HDM tablet is already available in Japan, Australia and South Korea under the brand name Actair and was approved for commercialization in New Zealand on September 8, 2017.